HCV genotype 4; A brief review

Journal of Gastroenterology and Hepatology Research

Volumn 3, Issue 2, 2014, Pages 968-976

  Afzal, Muhammad Sohail ^a   Elreheem, Amany Abd ^b   Ragaa, Ahmed ^b   Wahid, Ahmed ^b  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^b Minia University   (Egypt)

Author keywords

Genotype 4; HCV; Treatment; Vaccine trials

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GAG PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; HOST FACTOR; INTERFERON; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; NUCLEOTIDE; PEGINTERFERON; RIBAVIRIN; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; CHIMERA; CHIMPANZEE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIFE CYCLE; LIVER; LIVER CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; RETROVIRUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; TREATMENT OUTCOME; VACCINATION; VIRUS GENOME; VIRUS LOAD; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84918534171     PISSN: 22243992     EISSN: 22246509     Source Type: Journal    
DOI: 10.6051/j.issn.2224-3992.2014.03.382     Document Type: Review

References (107)

1. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des 2008 14: 1646-1654.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
3. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2009; 107: 14757-14762.
4. Mahboobi N, Porter SR, Karayiannis P, Alavian SM. Dental treatment as a risk factor for hepatitis B and C viral infection. A review of the recent literature. J Gastrointestin Liver Dis 2013; 22: 79-86.
5. Gentile I, Di Flumeri G, Scarica S, Frangiosa A, Foggia M, Reynaud L, Borgia G. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013; 65: 83-84.
6. Guadagnino V, Stroffolini T, Caroleo B, Menniti Ippolito F, Rapicetta M, Ciccaglione AR, Chionne P, Madonna E, Costantino A, De Sarro G et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis 2013; 45 403-407.
7. Kim JY, Cho J, Hwang SH, Kil H, Bae SH, Kim YS, Lee HC, Jeong SH Behavioral and healthcare-associated risk factors for chronic hepatitis C virus infection in Korea. J Korean Med Sci 2012; 27 1371-1377.
8. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52 1-36; quiz CE31-34.
9. Gurtsevitch VE. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc) 2008; 73: 504-513.
10. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI and Hellen CU. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A 2001; 98: 7029-7036.
11. Otto GA, Puglisi JD. The pathway of HCV IRES-mediated translation initiation. Cell 2004; 119: 369-380.
12. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
13. Goffard A, Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 2003; 85: 295-301.
14. Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J, Hahn YS, Rice CM, Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J Virol 1997; 71: 697-704.
15. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J Characterization of the envelope glycoproteins associated with infectious hepatitis C virus 2010; J Virol 84: 10159-10168.
16. Kuiken C, Simmonds P. Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 2009; 510: 33-53.
17. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112.
18. Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, Ono SK, Takahashi-Nakaguchi A, Gonoi T, Yokosuka O. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One, 8, e73615.
19. Negro F, Alberti A. The global health burden of hepatitis C virus infection Liver Int 2011; 31: Suppl 2, 1-3.
20. Zhao L, Feng Y, Xia XS. The different epidemic and evolution of HCV genotypes. Yi Chuan 2012; 34: 666-672.
21. Liberto MC, Marascio N, Zicca E, Matera G. Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis 2012; 12: Suppl 2, S4.
22. Panasiuk A, Flisiak R, Mozer-Lisewska I, Adamek A, Tyczyno M, Halota W, Pawlowska M, Stanczak J, Berak H, Wawrzynowicz-Syczewska M, Boron-Kaczmarska A, Lapinski TW, Grzeszczuk A, Piekarska A, Tomasiewicz K, Jablkowski M, Kryczka W, Zarebska-Michaluk D, Stepien P, Garlicki AM, Kozlowska J, Wiercinska-Drapalo A, Zasik E, Mazur W, Dobracka B, Dobracki W, Simon K, Ryzko J, Pawlowska J, Dzierzanowska-Fangrat K, Januszkiewicz-Lewandowska D, Szenborn L, Zaleska I, Rokitka M, Strawinska E, Balinowska K, Smiatacz T, Stalke P, Sikorska K, Lakomy A, Zdrojewski M, Lachowicz A. Distribution of HCV genotypes in Poland. Przegl Epidemiol 2013; 67, 11-16, 99-103.
23. Afzal MS, Anjum S, Zaidi NU. Effect of Functional Interleukin-10 Polymorphism on Pegylated Interferon-alpha Plus Ribavirin Therapy Response in Chronic Hepatitis C Virus Patients Infected With 3a Genotype in Pakistani Population. Hepat Mon 2014; 13: e10274.
24. Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, ShafiT, Ashraf M, Andleeb S. Sequence and structural analysis of 3' untranslated region of hepatitis C virus, genotype 3a, from pakistani isolates. Hepat Mon 2013; 13: e8390.
25. Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M. Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of the HCV NS5B Prote in. Hepat Mon 2012; 12: e6142.
26. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31: Suppl 2, 61-80.
27. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010; 202: 862-866.
28. Tokita H, Shrestha SM, Okamoto H, Sakamoto M, Horikita M, Iizuka H, Shrestha S, Miyakawa Y, Mayumi M. Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. J Gen Virol 1994; 75 (Pt 4): 931-936.
29. Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Lesmana LA, Miyakawa Y, Mayumi M. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77 (Pt 2): 293-301.
30. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Brechot C, Paranhos-Baccala G, Lotteau V. Characterization of Low-and Very-Low-Density Hepatitis C Virus RNA-Containing Particles. J Virol 2002; 76: 6919-6928.
31. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428.
32. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003; 100: 14199-14204.
33. Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology 2006; 348: 1-12.
34. Bartenschlager R. The hepatitis C virus replicon system: from basic research to clinical application. J Hepatol 2005; 43: 210-216.
35. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete Replication of Hepatitis C Virus in Cell Culture. Science 2005; 309: 623-626.
36. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
37. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9299.
38. Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zayadi AR, Kew MC, Conradie J, Lin CK, Marsden H et al. Use of NS-4 peptides to identify type specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol 1995; 76 (Pt 7): 1737-1748.
39. Rapicetta M, Argentini C, Dettori S, Spada E, Pellizzer G, Gandin C. Molecular heterogeneity and new subtypes of HCV genotype 4. Res Virol 1998; 149: 293-297.
40. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74 (Pt 11): 2391-2399.
41. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74 (Pt 4): 661-668.
42. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997; 78 (Pt 6): 1341-1347.
43. Timm J, Neukamm M, Kuntzen T, Kim AY, Chung RT, Brander C, Lauer GM, Walker BD, Allen TM. Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat 2007; 14: 330-337.
44. Lohmann V, Korner F, Koch J, Herian U, Theilmann L. Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
45. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-3190.
46. Grobler JA, Markel EJ, Fay JF, Graham DJ, Simcoe AL, Ludmerer SW, Murray, EM, Migliaccio G, Flores OA. Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase. J Biol Chem 2003; 278: 16741-16746.
47. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time-and temperature-dependent activation of hepatitis C virus for low-pH triggered entry. J Virol 2006; 80: 1734-1741.
48. Abe K, Ikeda M, Dansako H, Naka K, Kato N. Cell cultureadaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res 2007; 125: 88-97.
49. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974.
50. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516-8523.
51. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76, 2997-3006.
52. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808-1817.
53. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001; 75: 4614-4624.
54. Maekawa S, Enomoto N, Sakamoto N, Kurosaki M, Ueda E, Kohashi T, Watanabe H, Chen CH, Yamashiro T, Tanabe Y, Kanazawa N, Nakagawa M, Sato C, Watanabe M. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. J Viral Hepat 2004; 11: 394-403.
55. Mori K, Abe K, Dansako H, Ariumi Y, Ikeda M, Kato N. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochem Biophys Res Commun 2008; 371: 104-109.
56. Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002; 304: 197-210.
57. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 2012; 56: 5365-5373.
58. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
59. Hsu M, Zhang J, Flint M, LogvinoffC, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of seudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 7271-7276.
60. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41: 265-274.
61. McKeating JA, Zhang LQ, LogvinoffC, Flint M, Zhang J, Yu J, Butera D, Ho DD, Dustin LB, Rice CM, Balfe P. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 2004; 78: 8496-8505.
62. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 2005; 102: 4560-4565.
63. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
64. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
65. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011; 140: 1032-1042.
66. Imhof I, Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 2010; 84: 4597-4610.
67. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
68. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen, Olsen J, Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 2008; 105: 997-1002.
69. Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J Virol 2011; 85: 8913-8928.
70. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714.
71. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T and Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847-856.
72. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995 92: 4942-4946.
73. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
74. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-930.
75. Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, Fujimoto Y, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Sakai A, Sakai Y, Honda M, Kaneko S, Wakita T, Chayama K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007; 581: 1983-1987.
76. Kimura T, Imamura M, Hiraga N, Hatakeyama T, Miki D, Noguchi C, Mori N, Tsuge M, Takahashi S, Fujimoto Y, Iwao E, Ochi H, Abe H, Maekawa T, Arataki K, Tateno C, Yoshizato K, Wakita T, Okamoto T, Matsuura Y, Chayama K. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 2008; 89: 2108-2113.
77. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, Maylin S, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-1669.
78. Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. How to optimizeHCV therapy in genotype 4 patients. Liver Int 2013; 33 Suppl 1: 41-45.
79. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. Pegylated interferon alpha 2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740.
80. Salomon JA, Weinstein MC, Hammitt JK and Goldie SJ. Costeffectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
81. Fan X, Mao Q, Zhou D, Lu Y, Xing J, Xu Y, Ray SC, Di Bisceglie AM. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009; 50: 1765-1772.
82. Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, Al-Hamoudi W, Ali SM, Al-Ashgar HI, Al-Mdani A et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 2013; 7: 533-538.
83. El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012; 50: 3886-3892.
84. Shaker OG, Sadik NA. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol, 2012; 27: 1842-1849.
85. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6.
86. Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008; 28: 141-152.
87. Papastergiou V, Dimitroulopoulos D, Skorda L, Lisgos P, Ketikoglou I, Kostas N, Karatapanis S. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 1217-1223.
88. Dimitroulopoulos D, Elefsiniotis I, Pavlidis C, Xinopoulos D, Tsamakidis K, Patsavela S, Kypreos D, Ferderigou A, Korkolis D, Koutsounas S et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-alpha2a and ribavirin: the role of rapid and early virologic response. Hepat Mon 10: 193-198.
89. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F; Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-467.
90. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, Zalata K, Abdel-Hamid M, Fontanet A, Mohamed MK, Esmat G. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112-1119.
91. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938.
92. Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 1998; 17: 220-230.
93. Mohamed AA, Nada OH, El Desouky MA. Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis. Diagn Pathol 2012; 7: 103.
94. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103: 7408-7413.
95. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 18285-18295.
96. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008; 82: 966-973.
97. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93 15394-15399.
98. Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. Arch Virol 2014; 159(1): 1-15.
99. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007; 22 Suppl 1: S108-111.
100. Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 2006; 33: S79-83.
101. Ryu SH, Fan X, Xu Y, Elbaz T, Zekri AR, Abdelaziz AO, Di Bisceglie AM. Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. J Med Virol 2009; 81: 844-847.
102. Sarma MP, Asim M, Medhi S, Bharathi T, Kar P. Hepatitis C virus related hepatocellular carcinoma: a case control study from India. J Med Virol 2012; 84: 1009-1017.
103. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-4370.
104. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-336.
105. Tsutsumi T, Suzuki T, Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Matsuura, Y, Kimura S, Koike K, Miyamura T. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002; 304: 415-424.
106. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu Shady MA. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol 2005; 11: 6624-6630.
107. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-946.